<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Recommendation 4:</italic> There has been no scientific evidence that allergy treatments either increase susceptibility to SARS‐CoV‐2 or the severity of COVID‐19 disease. Pediatric allergists should treat patients with allergic asthma, allergic rhinitis, or other allergy conditions according to usual guidelines,
 <xref rid="pai13262-bib-0024" ref-type="ref">
  <sup>24</sup>
 </xref> without restricting the use of any specific medication. One exception to this is the advice to withhold biologics during acute COVID19 disease. In addition, there is also reason to believe that proper treatment of these diseases might prevent unnecessary visits to physicians and hospitals and thus reduce the risk of being exposed to the SARS‐COV‐2 virus. Of note, the Global Initiative for Asthma (GINA) recommends avoiding the use of nebulizers for asthma attacks due to the increased risk of disseminating COVID‐19 (to other patients and to physicians, nurses, and other personnel); thus, pressurized metered‐dose inhaler (pMDI) via a spacer is the preferred treatment during severe attacks.
 <xref rid="pai13262-bib-0028" ref-type="ref">
  <sup>28</sup>
 </xref>
</p>
